SG11201900181RA - Insulin analogs - Google Patents
Insulin analogsInfo
- Publication number
- SG11201900181RA SG11201900181RA SG11201900181RA SG11201900181RA SG11201900181RA SG 11201900181R A SG11201900181R A SG 11201900181RA SG 11201900181R A SG11201900181R A SG 11201900181RA SG 11201900181R A SG11201900181R A SG 11201900181RA SG 11201900181R A SG11201900181R A SG 11201900181RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- utah
- insulin analogs
- victoria
- salt lake
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 8
- 101150033195 Victoria gene Proteins 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000013078 crystal Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241001638933 Cochlicella barbara Species 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 102000003746 Insulin Receptor Human genes 0.000 abstract 1
- 108010001127 Insulin Receptor Proteins 0.000 abstract 1
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 235000007164 Oryza sativa Nutrition 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 235000009566 rice Nutrition 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000002435 venom Substances 0.000 abstract 1
- 210000001048 venom Anatomy 0.000 abstract 1
- 231100000611 venom Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
- C30B29/58—Macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/02—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Metallurgy (AREA)
- Materials Engineering (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016902883A AU2016902883A0 (en) | 2016-07-22 | Insulin Analogs | |
| US201762483118P | 2017-04-07 | 2017-04-07 | |
| PCT/AU2017/050758 WO2018014091A1 (en) | 2016-07-22 | 2017-07-21 | Insulin analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900181RA true SG11201900181RA (en) | 2019-02-27 |
Family
ID=65524551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900181RA SG11201900181RA (en) | 2016-07-22 | 2017-07-21 | Insulin analogs |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11248034B2 (de) |
| EP (1) | EP3487876A4 (de) |
| JP (2) | JP7143275B2 (de) |
| KR (2) | KR102529353B1 (de) |
| CN (2) | CN110072884B (de) |
| AU (1) | AU2021269301B2 (de) |
| BR (1) | BR112019000991A2 (de) |
| CL (1) | CL2019000159A1 (de) |
| CR (1) | CR20190096A (de) |
| IL (1) | IL264330B2 (de) |
| MA (1) | MA45727A (de) |
| MX (1) | MX2019000829A (de) |
| RU (1) | RU2769476C2 (de) |
| SG (1) | SG11201900181RA (de) |
| ZA (1) | ZA201901095B (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018045018A1 (en) * | 2016-08-30 | 2018-03-08 | Board Of Regents, The University Of Texas System | Production of seleno-biologics in genomically recoded organisms |
| WO2023229624A1 (en) * | 2022-05-26 | 2023-11-30 | Transdermal Delivery Solutions Corp. (D.B.A. Hypospray Pharma) | Transdermal insulin formulations and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2104305C1 (ru) | 1986-08-29 | 1998-02-10 | Ново Нордиск А.С. | Аналоги инсулина человека, способ их получения, раствор для инъекций |
| WO2005095443A1 (ja) * | 2004-03-31 | 2005-10-13 | Cardio Incorporated | ペプチド改変を利用したドラッグデリバリーシステム |
| MX2009002999A (es) | 2006-09-22 | 2009-04-01 | Novo Nordisk As | Analogos de insulina resistentes a proteasa. |
| US7790677B2 (en) * | 2006-12-13 | 2010-09-07 | Elona Biotechnologies | Insulin production methods and pro-insulin constructs |
| MX2011001181A (es) * | 2008-07-31 | 2011-04-05 | Univ Case Western Reserve | Insulina estabilizada con halogeno. |
| US9200053B2 (en) * | 2008-07-31 | 2015-12-01 | Case Western Reserve University | Insulin analogues containing penta-fluoro-Phenylalanine at position B24 |
| EP2376531A1 (de) * | 2008-12-09 | 2011-10-19 | Novo Nordisk A/S | Neue insulinanaloga |
| US8399407B2 (en) | 2009-09-17 | 2013-03-19 | Case Western Reserve University | Non-standard insulin analogues |
| EA201400030A1 (ru) | 2011-06-17 | 2014-07-30 | Галозим, Инк. | Способ непрерывного подкожного введения инсулина с использованием фермента, разрушающего хиалуронан |
| CA2904332A1 (en) * | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
| KR20150138251A (ko) * | 2013-03-15 | 2015-12-09 | 케이스 웨스턴 리저브 유니버시티 | 부위 2 인슐린 유사체 |
| MX2015017274A (es) * | 2013-06-14 | 2016-08-04 | Harvard College | Moduladores del receptor del polipéptido insulina estabilizados. |
| WO2018014091A1 (en) | 2016-07-22 | 2018-01-25 | University Of Utah Research Foundation | Insulin analogs |
-
2017
- 2017-07-21 KR KR1020197004760A patent/KR102529353B1/ko active IP Right Grant
- 2017-07-21 RU RU2019100497A patent/RU2769476C2/ru active
- 2017-07-21 CN CN201780050247.6A patent/CN110072884B/zh active Active
- 2017-07-21 US US16/319,450 patent/US11248034B2/en active Active
- 2017-07-21 BR BR112019000991A patent/BR112019000991A2/pt unknown
- 2017-07-21 IL IL264330A patent/IL264330B2/en unknown
- 2017-07-21 JP JP2019503259A patent/JP7143275B2/ja active Active
- 2017-07-21 MA MA045727A patent/MA45727A/fr unknown
- 2017-07-21 MX MX2019000829A patent/MX2019000829A/es unknown
- 2017-07-21 KR KR1020237015079A patent/KR20230070049A/ko not_active Application Discontinuation
- 2017-07-21 EP EP17830123.0A patent/EP3487876A4/de active Pending
- 2017-07-21 SG SG11201900181RA patent/SG11201900181RA/en unknown
- 2017-07-21 CN CN202310855095.4A patent/CN116874584A/zh active Pending
- 2017-07-21 CR CR20190096A patent/CR20190096A/es unknown
-
2019
- 2019-01-21 CL CL2019000159A patent/CL2019000159A1/es unknown
- 2019-02-20 ZA ZA2019/01095A patent/ZA201901095B/en unknown
-
2021
- 2021-11-16 AU AU2021269301A patent/AU2021269301B2/en active Active
-
2022
- 2022-01-04 US US17/568,698 patent/US20220340636A1/en active Pending
- 2022-09-14 JP JP2022146483A patent/JP2022191233A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL264330A (de) | 2019-03-31 |
| RU2019100497A3 (de) | 2021-05-11 |
| MX2019000829A (es) | 2019-08-29 |
| MA45727A (fr) | 2019-05-29 |
| EP3487876A4 (de) | 2020-02-19 |
| NZ750355A (en) | 2023-10-27 |
| CL2019000159A1 (es) | 2019-08-16 |
| EP3487876A1 (de) | 2019-05-29 |
| AU2021269301B2 (en) | 2023-12-21 |
| JP2022191233A (ja) | 2022-12-27 |
| IL264330B2 (en) | 2024-05-01 |
| CN110072884A (zh) | 2019-07-30 |
| AU2021269301A1 (en) | 2021-12-09 |
| US20220340636A1 (en) | 2022-10-27 |
| KR20190039719A (ko) | 2019-04-15 |
| RU2019100497A (ru) | 2020-08-24 |
| KR20230070049A (ko) | 2023-05-19 |
| US11248034B2 (en) | 2022-02-15 |
| KR102529353B1 (ko) | 2023-05-04 |
| CN116874584A (zh) | 2023-10-13 |
| CR20190096A (es) | 2019-09-16 |
| CN110072884B (zh) | 2023-07-28 |
| JP2019534843A (ja) | 2019-12-05 |
| US20190241640A1 (en) | 2019-08-08 |
| ZA201901095B (en) | 2022-04-28 |
| RU2769476C2 (ru) | 2022-04-01 |
| JP7143275B2 (ja) | 2022-09-28 |
| IL264330B1 (en) | 2024-01-01 |
| BR112019000991A2 (pt) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201808821WA (en) | Agonistic antibodies that bind human cd40 and uses thereof | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201808076UA (en) | Facilitating vehicle driving and self-driving | |
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
| SG11201903450YA (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201804205UA (en) | Media mixing chamber | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto |